Business
AbbVie Stock Rises 3.2% to Record Territory on Momentum Ahead of Q2 Report
NORTH CHICAGO, Ill. — Shares of AbbVie Inc. advanced 3.2% in morning trading Tuesday, reaching a fresh 52-week high as investors positioned ahead of the company’s second-quarter earnings report and continued to focus on the strength of its immunology portfolio and recent pipeline moves.
AbbVie stock rose $8.20 to $265.05 as of 11:16 a.m. EDT, extending a multi-month rally that has lifted the shares more than 30% over the past three months. The move pushed the stock into new high territory amid elevated interest in the company’s key growth drivers, Skyrizi and Rinvoq, and anticipation of results due Friday, July 31.
The pharmaceutical company is scheduled to report second-quarter 2026 financial results before the market opens on July 31, followed by a conference call. Analysts are watching for updates on revenue growth, the performance of its immunology franchise, and any further commentary on full-year guidance after an earlier adjustment related to acquired in-process research and development expenses.
In the first quarter, AbbVie delivered worldwide net revenues of $15.0 billion, up 12% on a reported basis and 10% on a constant-currency basis. Adjusted earnings per share came in at $2.65, exceeding the consensus estimate of $2.59. The company raised its full-year adjusted EPS guidance at that time.
Chairman and Chief Executive Officer Robert A. Michael said at the time: “AbbVie is off to an excellent start to the year, with first quarter results exceeding our expectations across our diverse portfolio. We are delivering top-tier growth and continue to strengthen our long-term outlook with pipeline advancements and strategic transactions.”
Skyrizi and Rinvoq have remained central to the growth story as AbbVie works through the ongoing erosion of Humira sales following the loss of exclusivity. The two immunology products have driven substantial share gains in their respective markets and have helped the company return to overall growth faster than many initially expected after the Humira patent cliff.
In June, AbbVie announced an agreement to acquire immunology-focused biopharma company Apogee Therapeutics in a deal valued at approximately $10.1 billion net of cash. The transaction, expected to close in the third quarter, was viewed by investors as a meaningful addition to the pipeline and contributed to a sharp one-day gain in the stock at the time of announcement. The company has continued to pursue earlier-stage assets aimed at supporting growth into the next decade.
Earlier in July, AbbVie updated its guidance to reflect acquired IPR&D and milestones expense of $291 million pretax in the second quarter, an unfavorable impact of 17 cents per share on both GAAP and adjusted non-GAAP diluted EPS. As a result, the company guided second-quarter adjusted diluted EPS to a range of $3.57 to $3.61 and full-year 2026 adjusted diluted EPS to $13.91 to $14.11, incorporating the second-quarter charge. The prior full-year range had been higher before the adjustment for the IPR&D expense.
Despite the guidance revision linked to the accounting impact of recent transactions, institutional interest has remained firm and several analysts have maintained or raised price targets. Consensus ratings lean toward Buy, with average targets clustered near current levels and some higher estimates reflecting confidence in the long-term trajectory of Skyrizi, Rinvoq and the broader pipeline.
AbbVie has emphasized its focus on building a diversified portfolio that includes immunology, oncology, neuroscience and other areas. Management has pointed to a clear line of sight to growth through the 2030s supported by on-market products and emerging assets. Recent business development activity has included investments in platforms spanning in vivo CAR-T, next-generation approaches in depression, multiple myeloma and obesity, among others.
The stock’s advance on Tuesday occurred on relatively light volume compared with recent averages, suggesting the move was driven more by positioning and broader sentiment toward defensive growth names in healthcare than by a single discrete catalyst. AbbVie continues to return capital to shareholders through a substantial dividend, currently yielding about 2.6% on an annualized basis following the most recent quarterly declaration of $1.73 per share.
Market participants will scrutinize Friday’s results for sequential trends in Skyrizi and Rinvoq sales, any commentary on competitive dynamics in immunology, progress on the Apogee integration timeline, and whether underlying operational performance supports confidence in the adjusted full-year outlook after the IPR&D adjustment. Oncology and other therapeutic areas will also draw attention as investors assess the balance of the portfolio beyond the two largest growth drivers.
AbbVie, spun off from Abbott Laboratories in 2013, has grown into one of the largest pure-play biopharmaceutical companies by market capitalization, currently valued near $470 billion. Its strategy has centered on replacing the Humira franchise with a broader set of high-growth assets while investing in research and development and selective acquisitions to extend the growth runway.
The shares have benefited this year from a combination of solid operational execution, successful pipeline advancement and a favorable valuation relative to some high-growth peers in the sector. The approach of the second-quarter report has added an incremental catalyst for trading activity as investors look for confirmation that the momentum observed in the first quarter has continued.
Analysts have noted that sustained double-digit growth in the key immunology products would reinforce the investment case even after accounting for the temporary impact of IPR&D charges. Free-cash-flow generation remains a core strength, supporting both reinvestment in the pipeline and ongoing capital returns.
As the market awaits the detailed numbers and management commentary later this week, Tuesday’s gain left AbbVie trading at the upper end of its recent range and near all-time highs on a split-adjusted basis. The performance underscores investor focus on the company’s ability to execute through the post-Humira transition and to convert pipeline opportunities into future commercial successes.
Trading in the broader healthcare sector provided a constructive backdrop, with several large-cap pharmaceutical and biotech names also advancing. For AbbVie specifically, the combination of near-term earnings visibility, the strategic Apogee transaction and continued strength in its core growth brands has kept the stock in favor among investors seeking exposure to large-cap biopharma with a mix of established cash flows and pipeline optionality.
Business
Ipsos SA 2026 Q2 – Results – Earnings Call Presentation (OTCMKTS:IPSOF) 2026-07-28
Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
Business
Earnings call transcript: CoStar Group tops EPS in Q2 2026, shares sink after hours

Earnings call transcript: CoStar Group tops EPS in Q2 2026, shares sink after hours
Business
S&P Global Inc. (SPGI) Presents at Orbit as the Next Data Frontier: Capital Flows, Risk, and Realities Transcript
Sarah James
Research Analyst
Hello, everyone, and welcome to today’s webinar. My name is Sarah James, and I lead the Tech, Media and Telecom News team within S&P Global Market Intelligence. It is my pleasure to moderate today’s webinar, Orbit as the Next Data Frontier: Capital Flows, Risks and Realities.
Before I introduce my guests, a few housekeeping items. We recognize that the topic of today’s webinar is of great interest, and we want this to be an interactive session and encourage you to submit questions for discussion. At the bottom of your screen, you will see a row of widget icons. These icons will allow you to interact with us throughout the session. I would like to point out the Q&A widget, which can be used to submit questions to the panelists as well as the survey widget. Please take time to fill out our short survey after the webinar. We really value your insight. The webinar is being recorded and an on-demand version will be available shortly after we conclude. If you encounter technical issues during the program, please try refreshing your browser. If issues persist, please use the Q&A widget to contact us and a member from our technical team will assist you.
Now it’s my pleasure to introduce today’s panel. I’ll begin with my colleague, John Fletcher, a senior analyst with S&P Global Market Intelligence to kick in. John leads the Americas research team for broadband, multichannel video and mobile with a focus on how the U.S. can close the broadband digital divide. Just as a hint, LEO satellites are
Business
Herc Holdings' Dip Offers An Entry Point
Herc Holdings' Dip Offers An Entry Point
Business
Earnings call transcript: Visa tops Q3 2026 estimates, raises outlook

Earnings call transcript: Visa tops Q3 2026 estimates, raises outlook
Business
TDAQ: The New Kid On The Nasdaq Block
TDAQ: The New Kid On The Nasdaq Block
Business
Johnson & Johnson agrees to $5.5B settlement over talc cancer claims
Check out whats clicking on FoxBusiness.com.
Johnson & Johnson (J&J) on Monday said it reached a settlement that it would pay an estimated $5.5 billion to settle tens of thousands of lawsuits alleging its baby powder and talc products cause ovarian cancer, which could end years of litigation on the subject.
The company said the proposed settlement would cover about 76,000 claims – including those that have been consolidated in federal court in New Jersey and related cases in state court – to cover nearly all the outstanding claims against J&J.
J&J previously settled most of the cases alleging its talc contained asbestos and caused mesothelioma.
The deal was confirmed by plaintiffs’ law firms on Monday, saying it was a good resolution after a decade-long court battle. The deal has to be accepted by 95% of the ovarian cancer claimants in state or federal court before it becomes final.
JOHNSON & JOHNSON CEO CREDITS TRUMP TAX POLICY FOR $55B US INVESTMENT PUSH, INCLUDING $1B IN FLORIDA

Johnson & Johnson announced a deal to settle talc powder lawsuits. (Lucas Jackson/Reuters)
J&J denied wrongdoing in its announcement of the settlement, saying that the plaintiffs weren’t able to prove their claims that the talc products caused cancer cases and that the settlement is a way of efficiently ending the litigation.
“While we are confident the company would ultimately have prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” said Erik Haas, worldwide VP of litigation at Johnson & Johnson.
The company expects to pay out $3 billion in 2027 and make further payments in 2028, though the deal could be worth more depending on how many people participate in the settlement.
JOHNSON & JOHNSON TO INVEST $1B IN PENNSYLVANIA MANUFACTURING FACILITY
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 266.75 | +0.72 | +0.27% |
Chris Seeger, an attorney who represents about 2,500 clients with talc claims and helped negotiate the settlement, said J&J could ultimately pay $7 billion or more as the settlement doesn’t cap the total payout and rather assigns specific values to qualifying ovarian cancer claims.
Seeger told Reuters in an interview that the plaintiffs “got a fair settlement, and our clients are going to be happy with it.”
The settlement comes after J&J secured a series of courtroom victories, including in individual trials, moves to disqualify plaintiffs’ lawyers and rulings against experts used by plaintiffs. The company won a significant court victory last week when a federal judge cast doubt on individual plaintiffs’ ability to prove that talc specifically caused their ovarian cancer.
TEXAS AG SUES KENVUE, J&J OVER ‘DECEPTIVELY MARKETING’ TYLENOL TO PREGNANT WOMEN

Johnson & Johnson has denied that its talc products caused cancer and said the settlement is a way to end the litigation. (Cristina Arias/Cover/Getty Images)
J&J has long denied that its talc products caused cancer, saying the products were safe and didn’t contain asbestos. It stopped selling talc-based baby powder in the U.S. in 2020 and switched to a cornstarch product.
The company attempted a legal strategy in which shell-company subsidiaries declared bankruptcy in an effort to settle the cases, though that proved unsuccessful.
It had a mixed record when talc cases went to trial, winning some outright and reducing verdicts on appeal, though it was hit with a multibillion-dollar verdict in a case brought by 22 women.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The new settlement only applies to existing claims and doesn’t address future lawsuits. The exclusion of future claims made more money available to current plaintiffs and also accelerated the payments so that all claims will be paid within 18 months instead of being spread out over more than a decade, Seeger said.
Reuters contributed to this report.
Business
Aevex stock rises on $88.1M precision strike system orders

Aevex stock rises on $88.1M precision strike system orders
Business
New bread base supports artisan-style production

The base features dried rye sourdough to deliver flavor and aroma.
Business
Mark Zuckerberg says AI power should be distributed, not centralized
Rosecliff founder and managing partner Mike Murphy discusses the chip sell-off as he highlights the U.S. becoming less dependent on Taiwan for the technology.
Meta CEO Mark Zuckerberg wrote in a new op-ed published on Tuesday that the rise of artificial intelligence should be used to empower all people rather than being centralized and controlled by a few institutions.
Zuckerberg wrote in The Wall Street Journal that people will be able to use superintelligence beyond human capacities in the next few years to create and discover new things, as well as drive economic growth and create opportunities. He noted that contrasts with some of the rhetoric from AI developers, and argued that diffusing AI access and its power broadly will lead to a better outcome.
“It is surprising that the discourse from many of those who are developing artificial intelligence is so filled with doom. I don’t understand why anyone who believes that AI will eliminate most jobs and much of humanity’s relevance would rush to build that future,” he wrote.
“The notion that AI is so dangerous that the only safe path is an extreme concentration of power seems dangerous. Historically, hoping that an absolute power will benevolently provide for humanity if sufficiently enlightened hasn’t led to safe or positive outcomes,” Zuckerberg explained.
ZUCKERBERG SAYS AI SHOULD EMPOWER PEOPLE, NOT REPLACE THEM, IN NEW META VISION

Meta CEO Mark Zuckerbreg argued that AI should be diffused rather than concentrated in a few institutions. ( John Nacion/Variety via Getty Images)
Zuckerberg said that there have been many transformative advances in technology throughout history that have stoked fears it would leave people behind, and that ultimately people enjoyed more prosperity, health and freedom as those technologies progressed.
“Putting power in people’s hands to pursue their own aspirations is how humanity has made the most progress. Novel ideas and major steps forward rarely originate from established institutions alone,” he wrote.
Zuckerberg alluded to how massive technological developments for humanity like flight, electricity and personal computing were advanced by individuals without deep ties to institutions. He said that as “everyone gains more powerful tools, each person will become more capable of shaping the future, not less.”
AI INNOVATION IS OUTPACING GOVERNANCE, LEAVING COMPANIES EXPOSED, EQUALAI WARNS

The rise of AI is leading to technological advances as well as investment in infrastructure, like new data centers. (Meta)
The Meta CEO acknowledged that there is a balance between the use of AI for automation and it being a tool that empowers innovation and enables people to expand skills and launch businesses, adding that if the balance leans toward automation it could have a negative impact on jobs and the economy.
“But if superintelligence is widely distributed, then I believe we will see more jobs in the future, not fewer. It will be significantly easier to start businesses without raising large amounts of capital.”
“I expect the economy will become more entrepreneurial with a greater number of people working at small businesses rather than larger companies,” he wrote.
PALANTIR CEO WARNS US AGAINST EUROPE’S AI REGULATION PATH, URGES TRUMP ADMIN TO NOT BAN OPEN MODELS

Zuckerberg said he thinks AI-powered superintelligence can bring about a positive future for humanity. (Reuters/Manuel Orbegozo)
Zuckerberg added that the development of superintelligence “will be the most profound technological advance we will see in our lifetimes.”
“Meta is committed to building with the principles of individual empowerment, invention and balance of power. The arc of human history has bent toward putting more power in people’s hands.”
“If these values lead the way, then I am optimistic that we can build a positive future for everyone,” he wrote.
-
Fashion4 days agoWeekend Open Thread: Brooks Brothers
-
Business7 days agoNew Jersey voter registration controversy explained: How 6,600 noncitizens got on the rolls, and what happens next
-
Tech2 days agoIntel is reversing course and bringing hyper-threading back to its server chips
-
Sports2 days agoCommonwealth Games boxing: Jadumani Singh seals dominant 5-0 win over Pakistan’s Sumama Rehman to enter quarter-finals | Commonwealth Games News
-
Crypto World6 days agoEthics, other provisions in crypto Clarity Act to be further discussed
-
Politics1 day agoLuke Littler dismantles Gerwyn Price to retain title in Blackpool
-
Sports5 days ago2026 3M Open leaderboard: Scottie Scheffler finds putter in Round 1, sits three back
-
Fashion5 days ago16 Dresses for the High Summer Event
-
News Videos2 days agoBITCOIN JUST ENTERED THIS CRITICAL ZONE…
-
Politics14 hours agoThe Part of the Electric Transition Nobody Wants to Discuss
-
News Videos5 days agoThe Peugeot Family: How 200 Years of an “Old Money” Dynasty Died in A Boardroom
-
Entertainment4 days agoA New Post-Apocalyptic Gundam Anime Series Blasts Into SDCC
-
Politics2 days agoSpain sweeps the board at 2026 World Cup with individual awards
-
Crypto World3 days agoRipple bought a bank in pieces. The $4 billion audit
-
Crypto World3 days agoXRP Ledger adds $2.6B as RWA inflows rank second
-
Crypto World5 days agoUniswap (UNI) pushes deeper into tokenized RWAs with permissioned trading pools
-
Tech4 days agoAnthropic launches Claude Opus 5, a cheaper AI model for coding, agents and enterprise workflows
-
Entertainment4 hours ago‘Stargate’ Creator’s New Sci-Fi Series Returns for Season 3 Tomorrow
-
Entertainment3 days agoSara Gilson Killed By Husband After Viral “Pedophile” TikTok Video
-
Crypto World7 days agoSablier Labs Enters Maintenance Mode, Halts Development

You must be logged in to post a comment Login